SV2A

Across TCGA pan-cancer cohorts, SV2A Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SV2A data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SV2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SV2A expression acts as an unfavorable survival marker, although some lineages such as STAD and SKCM show a favorable association.

CESC, LUSC, and PRAD are the cancer types where SV2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	IV	0.121	0.591	.029	18	view →
LUSC	DFS	Median	II,III,IV	0.079	0.749	.010	18	view →
PRAD	DFS	Median	All	0.526	0.936	<.001	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
HNSC	DFS	Median	III,IV	0.101	0.680	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	DFS	Median	III,IV	0.722	0.324	.034	3	view →
SKCM	DFS	Median	II,III,IV	0.911	0.669	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SV2A–CESC (OS)

Open the CESC breakdown →